Kriya Therapeutics has closed an oversubscribed Series D funding round, raising $320m, aimed at propelling its gene therapy pipeline targeting chronic diseases with significant unmet medical needs.
RESEARCH TRIANGLE PARK, N.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. (“Kriya”), a clinical-stage biopharmaceutical company developing gene therapies to address common chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results